SCHEMBL2910554

SCHEMBL2910554

O=S(=O)(Nc1cccc2nc(Nc3cccc(C(F)(F)F)c3)ccc12)c1cc(F)cc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.52
MAPT P10636 5/20 0.47
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
TP53 P04637 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
RAF1 P04049 1/20 0.44
BRAF P15056 1/20 0.44
ABCG2 Q9UNQ0 2/20 0.43
IDH1 O75874 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
AURKA O14965 3/20 0.43
FFAR1 O14842 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CDK7 P50613 1/20 0.42
CCNH P51946 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2904980 0.91 EGFR (0.44) CLK1MAPTKDM4EGAATP53
SCHEMBL2906872 0.86 SLC10A2 (0.45) MAPTKDM4ETP53KMT2AMEN1
SCHEMBL2901922 0.83 MAPT (0.40) CLK1MAPTGAATP53KMT2A
SCHEMBL2904870 0.83 MEN1 (0.49) MAPTKDM4ETP53KMT2AMEN1
SCHEMBL2907742 0.80 RECQL (0.53) CLK1MAPTKDM4EGAAKMT2A
SCHEMBL2906708 0.75 IDO1 (0.42) CLK1MAPTKDM4EGAAKMT2A
SCHEMBL2905319 0.75 LMNA (0.44) CLK1MAPTKDM4EGAAKMT2A
SCHEMBL2907020 0.75 SLC40A1 (0.49) CLK1MAPTKDM4EGAAKMT2A
SCHEMBL2902345 0.74 EPHB4 (0.47) CLK1MAPTKDM4EGAAKMT2A
SCHEMBL2905387 0.74 RECQL (0.39) CLK1MAPTKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 CLK1 3082/4885MAPT 1716/4885KDM4E 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.